Barclays lowered the firm’s price target on Surgery Partners (SGRY) to $14 from $18 and keeps an Equal Weight rating on the shares post the Q4 report. While expectations were low, Surgery’s results still disappointed and its new issues will take time to sort out, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Closing Bell Movers: MongoDB down over 20% after soft Q1 guidance
- Surgery Partners Announces Share Buyback and 2026 Outlook
- Surgery Partners sees FY26 revenue $3.35B-$3.45B, consensus $3.56B
- Surgery Partners announces new $200M share repurchase program
- Surgery Partners reports Q4 adjusted EPS 12c, consensus 30c